Trial Profile
Characterization of ovulation inhibition of a new vaginal delivery system containing trimegestone - an open-label, single-centre study in healthy females of childbearing potential
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2020
Price :
$35
*
At a glance
- Drugs Estriol/trimegestone (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Evestra
- 19 Jun 2020 Results (n=80) determining the lowest trimegestone (TMG) dose, administered via a vaginal ring, that effectively inhibited ovulation published in the Contraception
- 24 Feb 2020 Status changed from recruiting to completed.
- 27 Jun 2018 New trial record